Home Premarket Biotech Digest: Novartis Earnings, Portola Lawsuits, Celgene's Orphan Drug
 

Keywords :   


Premarket Biotech Digest: Novartis Earnings, Portola Lawsuits, Celgene's Orphan Drug

2015-07-23 11:13:42| Biotech - Topix.net

Xarelto, Eliquis and other anticoagulants that face products liability lawsuits have made deals with Portola, which is developing an antidote. One of the first anticoagulants, warfarin, was used as rat poison for 50 years before it began life as a blood thinner - and the only reason it did that was because a US Army sergeant who tried to kill himself with it was cured when treated with Vitamin K. Moral of the story- if you want to develop an anticoagulant, you better also develop its antidote, or you could bungle your way into multiple lawsuits.

Tags: drug earnings digest biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
20.05USDA moves to electronic identification tags
20.05Better pasture and hay conditions anticipated for 2024
20.05Panasonic offers Fire TV, Google TV and Powered by TiVo
20.05Eutelsat reports results for the period ended 31 March 2024
20.05Producers to be paid grid premiums for AngusLink Beef Scores
20.05WCC Re-elects Tom Bowtell for Second Term as President, Recognizes Contributions of Andy Doyle
20.05May/June 2024 Digital Edition of National Hog Farmer now available
20.05DKSH Extends Distribution Agreement with KRONOS in Asia Pacific
More »